AGP Picks
View all

The Boston Examiner: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Boston Examiner.

Press releases published on November 12, 2026

Merlin, Inc. Reports Third Quarter 2026 Results
Fractyl Health Reports Third Quarter 2026 Financial Results and Business Updates
Akari Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Continued Progress Toward Clinical Development of Differentiated ADC Payload Platform
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
Prime Medicine Reports Third Quarter 2026 Financial Results and Provides Business Updates
Akamai Announces Closing of $2.5 Billion Offering of Convertible Senior Notes
NEW BOOK RECLAIMS THE CULTURAL, ECOLOGICAL, AND INTELLECTUAL HISTORY OF MITHILA
ENVX DOWN 14%: Enovix Investigated for Securities Fraud; Investors Should Contact Block & Leviton to Possibly Recover Losses
Intellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026
Foundation Launches Universal Ethereum Signer in Beta, First on Passport Hardware
AI Disruption in Virtual Mirror Technology Signals Inflection Point for Retail Investment
MIT researchers create roadmap to help organizations mitigate AI risks
Coralogix Recognized as a Market Shaper in the October 2026 Gartner® Emerging Market Quadrant for AI FinOps Tools – Startup Vendors
Holiday Party Budgets Climb 13% as Employees Gather for Year-End Workplace Celebrations
7AI Launches PLAID ELITE: Incident Response to Deliver Answers in Hours as AI-Driven Attacks Outpace Response Firms
Alpha Tau to Host Investor Call to Review New Data from the Alpha DaRT® Recurrent Glioblastoma REGAIN Trial
Avalyn Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Aktis Oncology Reports Third-Quarter Financial Results and Highlights Clinical Trial Progress
Immuneering Announces New Potentially Registrational Phase 2 Trial Evaluating Atebimetinib with Chemotherapy in Anaplastic Thyroid Cancer
Immuneering to Collaborate with Astellas on Clinical Studies of Investigational CLDN18.2 Programs in Combination with Atebimetinib for Pancreatic Cancer Patients

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

The Boston Examiner

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.